ILMN ILLUMINA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1110803 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY27.5%
TTM EPS YoY30.3%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin67.9%
Operating margin21.2%
Net margin19.7%
FCF margin23.3%
EBITDA margin27.1%
Returns
ROE32.4%
ROA13.8%
ROIC (approx.)51.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity0.00x
Current ratio2.63x
Interest coverage9.80x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-27 | 2026Q22026-06-28 | 2026Q12026-03-29 | 2025Q4*2025-12-28 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q4*2024-12-29 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.13B | $1.16B | $1.09B | $1.16B | $1.08B | $1.06B | $1.04B | $1.10B |
| Cost of revenue | $299.00M | $389.00M | $370.00M | $400.00M | $351.00M | $364.00M | $358.00M | $376.00M |
| Gross profit | $830.00M | $770.00M | $721.00M | $759.00M | $733.00M | $695.00M | $683.00M | $728.00M |
| R&D expense | $244.00M | $252.00M | $240.00M | $239.00M | $229.00M | $247.00M | $252.00M | $256.00M |
| SG&A expense | $281.00M | $273.00M | $272.00M | $309.00M | $277.00M | $234.00M | $267.00M | $279.00M |
| Operating income | $305.00M | $245.00M | $209.00M | $201.00M | $227.00M | $214.00M | $164.00M | $175.00M |
| Interest expense | $24.00M | $24.00M | $24.00M | $26.00M | $25.00M | $25.00M | $25.00M | $25.00M |
| Pretax income | $264.00M | $260.00M | $157.00M | $377.00M | $220.00M | $306.00M | $182.00M | $187.00M |
| Income tax | $44.00M | $53.00M | $23.00M | $43.00M | $70.00M | $71.00M | $51.00M | $0 |
| Net income | $220.00M | $207.00M | $134.00M | $334.00M | $150.00M | $235.00M | $131.00M | $186.00M |
| EBITDA | $357.00M | $296.00M | $260.00M | $318.00M | $294.00M | $282.00M | $216.00M | $246.00M |
| EPS (basic) | 1.46 | 1.37 | 0.88 | — | 0.98 | 1.49 | 0.83 | — |
| EPS (diluted) | 1.43 | 1.35 | 0.87 | — | 0.98 | 1.49 | 0.82 | — |
| Weighted avg. shares (diluted) | 154.00M | 153.00M | 154.00M | — | 154.00M | 157.00M | 159.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.29B | $1.04B | $1.09B | $1.42B | $1.05B | $934.00M | $1.11B | $1.13B |
| Short-term investments | $48.00M | $128.00M | $66.00M | $215.00M | $228.00M | $221.00M | $124.00M | $93.00M |
| Receivables | $738.00M | $764.00M | $738.00M | $854.00M | $729.00M | $701.00M | $699.00M | $735.00M |
| Inventory | $667.00M | $629.00M | $611.00M | $564.00M | $590.00M | $575.00M | $537.00M | $547.00M |
| Current assets | $3.04B | $2.83B | $2.74B | $3.29B | $2.80B | $2.64B | $2.67B | $2.75B |
| PP&E, net | $731.00M | $745.00M | $755.00M | $759.00M | $748.00M | $764.00M | $782.00M | $815.00M |
| Goodwill | $1.28B | $1.28B | $1.28B | $1.11B | $1.11B | $1.11B | $1.11B | $1.11B |
| Intangibles | $391.00M | $410.00M | $430.00M | $210.00M | $225.00M | $238.00M | $278.00M | $295.00M |
| Total assets | $6.81B | $6.65B | $6.56B | $6.64B | $6.18B | $6.09B | $6.18B | $6.30B |
| Current liabilities | $1.16B | $1.58B | $1.57B | $1.58B | $1.96B | $1.46B | $1.44B | $1.55B |
| Total liabilities | $3.67B | $3.81B | $3.88B | $3.92B | $3.80B | $3.83B | $3.81B | $3.93B |
| Shareholders' equity | $3.15B | $2.84B | $2.68B | $2.72B | $2.38B | $2.26B | $2.37B | $2.37B |
| Shares outstanding | — | — | — | 153.00M | — | — | — | 159.00M |
| Cash flow statement | ||||||||
| Operating cash flow | $419.00M | $201.00M | $289.00M | $321.00M | $284.00M | $234.00M | $240.00M | $364.00M |
| Capital expenditure | $40.00M | $40.00M | $38.00M | $55.00M | $31.00M | $30.00M | $32.00M | $29.00M |
| Free cash flow | $379.00M | $161.00M | $251.00M | $266.00M | $253.00M | $204.00M | $208.00M | $335.00M |
| Investing cash flow | $50.00M | -$122.00M | -$366.00M | $108.00M | -$51.00M | -$49.00M | -$63.00M | -$48.00M |
| Financing cash flow | -$222.00M | -$129.00M | -$251.00M | -$63.00M | -$115.00M | -$371.00M | -$195.00M | -$47.00M |
| Depreciation & amortization | $52.00M | $51.00M | $51.00M | $117.00M | $67.00M | $68.00M | $52.00M | $71.00M |
| Stock-based compensation | $75.00M | $72.00M | $60.00M | $63.00M | $70.00M | $69.00M | $73.00M | $79.00M |
| Share buybacks | $9.00M | $128.00M | $242.00M | $42.00M | $130.00M | $370.00M | $200.00M | $17.00M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.